Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand which index funds are best for IRAs in 2024, with guidance on diversification, costs, and long-term retirement goals.
24,195 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Insider buying can hint at confidence from leadership, but it isn’t a crystal ball. This guide explains how to interp...
Chevron's CEO warns that jet fuel shortages may push aviation costs higher as carriers trim schedules and consumers f...
Zcash (ZEC) surged about 40% in a single session, reclaiming a spot among crypto's top names as privacy-focused coins...
HomeServices of America has named Jason Waugh to succeed Vince Leisey as CEO of HSF Affiliates, with a transition set...
The FDA approved two fruit-flavored vape lines from a Los Angeles company, a notable policy reversal that comes as po...
Alphabet signals a strategic shift toward edge AI, with Chrome devices potentially shouldering more inference work. T...
A 50-year-old professional earning $210,000 unveils a four-account plan to craft tax-free retirement income by 62, bl...
A private Dallas developer secures a government-backed funding package to build a Gulf of Mexico deepwater oil termin...
Datadog stock climbs after upbeat Q1 results and fresh price targets near $225, underscoring a broader shift to AI-dr...
Is AMD stock still a good buy or is it too late to join the rally? This practical guide breaks down timing, value, an...
Chinese automakers are shifting from passenger cars to commercial fleets, challenging Ford's margins and strategy. Th...